GRTX · As filed with the SEC
Galera Therapeutics cash flow statement, by fiscal year
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Operating activities: | ||||
| Net loss | 149,049,000 | (18,957,000) | (59,082,000) | (62,222,000) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||
| Acquired in-process research and development | 0 | 3,843,000 | — | — |
| Depreciation and amortization | 0 | 20,000 | 259,000 | 114,000 |
| Noncash interest expense | — | 0 | 11,414,000 | 11,571,000 |
| Share-based compensation expense | 410,000 | 2,545,000 | 5,560,000 | 7,164,000 |
| Write-off of acquired intangible asset | 0 | 2,258,000 | — | — |
| Write-off of goodwill | 0 | 881,000 | — | — |
| Deferred tax benefit | 0 | 203,000 | 0 | (70,000) |
| Change in fair value of warrants | (294,000) | (452,000) | — | — |
| Gain on sale of dismutase mimetics assets | (3,500,000) | — | — | — |
| Gain on extinguishment of debt | (151,049,000) | — | — | — |
| Loss on disposal of property and equipment | 0 | 48,000 | (72,000) | — |
| Changes in operating assets and liabilities: | ||||
| Refundable PDUFA fee | — | 0 | 3,242,000 | (3,242,000) |
| Prepaid expenses and other current assets | 357,000 | 2,295,000 | 514,000 | 2,529,000 |
| Other assets | (1,000) | 89,000 | 1,932,000 | 330,000 |
| Accounts payable | (1,010,000) | (1,416,000) | (2,206,000) | (1,463,000) |
| Accrued expenses | (11,000) | (3,058,000) | (6,305,000) | 2,121,000 |
| Other liabilities | 0 | (38,000) | (104,000) | (258,000) |
| Cash used in operating activities | (6,049,000) | (12,145,000) | (44,848,000) | (43,426,000) |
| Investing activities: | ||||
| Purchases of short-term investments | — | 0 | (22,643,000) | (59,891,000) |
| Proceeds from sales of short-term investments | — | 0 | 49,995,000 | 83,910,000 |
| Cash paid for acquisition of Nova | 0 | (50,000) | — | — |
| Purchase of property and equipment | — | 0 | (59,000) | (25,000) |
| Proceeds from sale of property and equipment | 0 | 4,000 | — | — |
| Proceeds from sale of dismutase mimetics asset | 3,500,000 | — | — | — |
| Cash provided by investing activities | 3,500,000 | (46,000) | 27,293,000 | 23,994,000 |
| Financing activities: | ||||
| Proceeds from royalty purchase agreement | — | — | — | 0 |
| Proceeds from the sale of common stock and common stock warrants in private placement, net of issuance costs | 635,000 | 2,223,000 | — | — |
| Proceeds from the sale of common stock and common stock warrants in registered direct offering, net of issuance costs | — | 0 | 27,598,000 | — |
| Proceeds from the sale of common stock under the Open Market Sale Agreement, net of issuance costs | — | — | 1,701,000 | 3,808,000 |
| Proceeds from the exercise of common stock warrants | — | — | 2,009,000 | — |
| Proceeds from the sale of common stock under the Open Market Sale Agreement, net of issuance costs | — | 0 | — | — |
| Proceeds from the exercise of common stock warrants | — | 0 | — | — |
| Proceeds from exercise of stock options | — | 0 | 188,000 | 81,000 |
| Cash provided by financing activities | 635,000 | 2,223,000 | 31,496,000 | 3,889,000 |
| Net decrease in cash and cash equivalents | (1,914,000) | (9,968,000) | 13,941,000 | (15,543,000) |
| Cash and cash equivalents at beginning of year | 8,289,000 | 18,257,000 | 4,316,000 | 19,859,000 |
| Cash and cash equivalents at end of year | 6,375,000 | 8,289,000 | 18,257,000 | 4,316,000 |
| Supplemental schedule of non-cash investing and financing activities: | ||||
| Purchase of property and equipment included in accounts payable and accrued expenses | — | — | — | 0 |
| Extinguishment of royalty purchase liability upon sale of dismutase mimetics assets | 151,049,000 | — | — | — |
| Issuance of Series B redeemable convertible preferred stock in asset acquisition | 0 | 2,577,000 | — | — |
| Accretion (amortization) of redeemable convertible preferred stock to redemption value | (1,795,000) | 1,795,000 | — | — |
| Subscription receivable in connection with private placement | 0 | 635,000 | — | — |
| Derecognition of lease liability and right-of-use asset due to lease termination | 0 | 1,212,000 | — | — |
| Acquisition costs in accounts payable | 0 | 869,000 | — | — |
| Right-of-use asset obtained in exchange for lease obligation | — | 0 | 1,310,000 | — |
| Sale of property and equipment in exchange for prepaid future services | — | 0 | 240,000 | — |
| Reclassification of warrant liability to additional paid-in capital | 761,000 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.